No link to cardiac valvulopathy was seen in cabergoline treated patients

No link to cardiac valvulopathy was seen in cabergoline treated patients

<p><strong>Objective:</strong> To evaluate the association between use of cabergoline in patients with prolactinoma and risk of developing clinically relevant cardiac valvular disease.</p> <p><strong>Method:</strong> This was a descriptive cross sectional st...

Detaylı Bibliyografya
Asıl Yazarlar:	K Dharshini, Noel Somasundaram, HMDPK Senevirathna, S Raj Kumar
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Sri Lanka College of Endocrinologists 2012-10-01
Seri Bilgileri:	Sri Lanka Journal of Diabetes Endocrinology and Metabolism
Konular:	prolactinoma cabergoline valvulopathy
Online Erişim:	https://sjdem.sljol.info/articles/4775

Benzer Materyaller

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Yazar:: Shruti Khare, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
Yazar:: Annabelle G Hayes, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
Yazar:: Youngki Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2014-09-01)

Spontaneous reduction of prolactinoma post cabergoline withdrawal
Yazar:: Sampath Kumar Venkatesh, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
Yazar:: Larisa Dzeranova, ve diğerleri
Baskı/Yayın Bilgisi: (2016-11-01)

Cabergoline-induced tricuspid regurgitation: Case report and review of literature
Yazar:: Mohammad Hayat Bhat, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
Yazar:: Bassam M Flamerz Arkawazi
Baskı/Yayın Bilgisi: (2020-01-01)

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors
Yazar:: Galina Afanas'evna Melnichenko, ve diğerleri
Baskı/Yayın Bilgisi: (2015-04-01)

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report
Yazar:: Luiz Augusto Casulari, ve diğerleri
Baskı/Yayın Bilgisi: (2019-06-01)

Management of prolactinoma with cabergoline treatment in a pregnant woman during her entire pregnancy
Yazar:: Sukhwinder Kaur Bajwa, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Subarachnoid Hemorrhage Due to Rupture of an Intracavernous Carotid Artery Aneurysm Coexisting with a Prolactinoma under Cabergoline Treatment
Yazar:: Nobuyuki Akutsu, ve diğerleri
Baskı/Yayın Bilgisi: (2014-03-01)

Second attempt of Cabergoline withdrawal in patients with prolactinomas after a failed first attempt : is it worthwhile?
Yazar:: Lucio eVilar, ve diğerleri
Baskı/Yayın Bilgisi: (2015-02-01)

The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
Yazar:: Zilya A. Kalmykova, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
Yazar:: Ana Carolina Correa e Castro, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Histopathologic characterization of lesios in rheumatic valvulopathy
Yazar:: R. Ricca, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

VISUAL FIELD DEFECTS SECONDARY TO CABERGOLINE USE IN A PATIENT WITH PITUITARY TUMOR
Yazar:: sylvia andrea araneda, ve diğerleri
Baskı/Yayın Bilgisi: (2015-02-01)

Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience
Yazar:: Tuğba Kontbay, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
Yazar:: Edward Mignone, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Makroprolaktinoma da Kabergolin Tedavisinin Etkinliği
Yazar:: Derya Buluş
Baskı/Yayın Bilgisi: (2017-09-01)

Temozolomide in treatment resistant prolactinomas
Yazar:: V. N. Shree, ve diğerleri
Baskı/Yayın Bilgisi: (2018-08-01)

Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin
Yazar:: Ludmila I. Astafyeva, ve diğerleri
Baskı/Yayın Bilgisi: (2018-03-01)

Pathogenesis, diagnosis and current treatment of prolactinoma: a review of the literature
Yazar:: Monika Szyszka, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

A clinical case of effective treatment of giant prolactinoma in patient with morbid obesity
Baskı/Yayın Bilgisi: (2014-06-01)

Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Yazar:: Cristina Laguna Benetti-Pinto, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
Yazar:: Irena A. Ilovayskaya, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Yazar:: Michele Basile, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Prolactinomas: evolution after menopause
Yazar:: Maria Susana Mallea-Gil, ve diğerleri

Lymphangioleiomyomatosis associated with prolactinoma: A case report and literature review
Yazar:: Yosuke Murakami, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
Yazar:: Motofumi Koguchi, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Cardiovascular Imaging in Pregnancy: Valvulopathy, Hypertrophic Cardiomyopathy, and Aortopathy
Yazar:: Haneen Ismail, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

CABERGOLINE IN PRACTICAL MAMMOLOGY
Yazar:: I. V. Vysotskaya, ve diğerleri
Baskı/Yayın Bilgisi: (2016-12-01)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
Yazar:: Sunita M C De Sousa
Baskı/Yayın Bilgisi: (2023-01-01)

Klinicheskiy sluchay gigantskoy prolaktin-sekretiruyushchey adenomy gipofiza u podrostka
Baskı/Yayın Bilgisi: (2010-06-01)

The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene
Yazar:: Laurent Vroonen, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
Yazar:: Claudia Pivonello, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Cabergoline-induced mania in a patient of pituitary microadenoma
Yazar:: Satyakam Mohapatra, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma
Yazar:: Mehnaz Mustary Shume, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Macroprolactinoma resistente aos agonistas dopaminérgicos: relato de caso Macroprolactinoma resistant to dopamine agonists: a case report
Yazar:: Rosana Maria dos Reis, ve diğerleri
Baskı/Yayın Bilgisi: (2004-09-01)

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
Yazar:: Muhammed Kizilgul, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Prolactinoma - which patients react favorably to cabergoline medication?
Yazar:: Karatas Savas, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)